Sanofi dreams of an ‘unencumbered’ future
Sanofi has reaped billions of dollars from stakes in other people’s drugs. But CEO Paul Hudson, about a year into his tenure, is plotting a more wholly owned future for the French pharmaceutical giant.
Speaking to STAT’s Matthew Herper, Hudson said Sanofi’s latest deal — trading $3.7 billion for partner Principia Biopharma — is a sign of things to come. The company is moving away from a lengthy and lucrative partnership with Regeneron. That has meant relying less on Regeneron’s scientists, liquidating a roughly $11 billion stake in the company, and using the proceeds to invest in Sanofi’s internal pipeline.
“We have a tremendous medicine in Dupixent,” Hudson said, referring to the Regeneron-invented treatment for autoimmune disorders. “But it is partnered. And where I want to be on the science is unencumbered, where possible.”
Read more.
Speaking to STAT’s Matthew Herper, Hudson said Sanofi’s latest deal — trading $3.7 billion for partner Principia Biopharma — is a sign of things to come. The company is moving away from a lengthy and lucrative partnership with Regeneron. That has meant relying less on Regeneron’s scientists, liquidating a roughly $11 billion stake in the company, and using the proceeds to invest in Sanofi’s internal pipeline.
“We have a tremendous medicine in Dupixent,” Hudson said, referring to the Regeneron-invented treatment for autoimmune disorders. “But it is partnered. And where I want to be on the science is unencumbered, where possible.”
Read more.
.png)
No hay comentarios:
Publicar un comentario